GSK news http://www.gsk.com/media/ GlaxoSmithKline is a leading healthcare company that helps people to do more, feel better and live longer. This RSS feed contains press releases and investor news. GSK CEO Andrew Witty dedicates albendazole facility in Nashik to WHO’s Global Programme to Eliminate LF http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10022.htm GSK CEO Andrew Witty today dedicated a new production facility at its Nashik site in India to the manufacture of albendazole, part of a combination treatment used within the World Health Organization’s Global Programme to Eliminate Lymphatic Filariasis. Fri, 22 Jan 2010 10:30:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10022.htm GlaxoSmithKline responds to US Senate Committee on Finance report on Avandia http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10021.htm Today, GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance’s January 2010 “Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia” (the “Staff Report”) by releasing a White Paper. Wed, 24 Feb 2010 14:30:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10021.htm GSK rejects conclusions of Senate Committee on Finance Staff Report on Avandia http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10020.htm The Staff Report of the Senate Committee on Finance draws conclusions on the safety of Avandia (rosiglitazone) that are based on analyses that are not consistent with the rigorous scientific evidence supporting the safety of the drug. Sat, 20 Feb 2010 21:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10020.htm GSK rejects conclusions reported in The New York Times story on Avandia http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10019.htm GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in the February 20, 2010, New York Times story. Sat, 20 Feb 2010 19:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10019.htm GSK receives positive opinions in Europe for Tyverb® (lapatinib) and Votrient™ (pazopanib) http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10018.htm GlaxoSmithKline (GSK) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued two positive opinions in the European Union for two of its cancer medicines. Fri, 19 Feb 2010 11:15:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10018.htm GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10017.htm Because the safety and health of our consumers is our primary concern, GlaxoSmithKline (GSK) Consumer Healthcare is issuing a Consumer Advisory warning consumers about the potential health risks associated with long-term excessive use of zinc-containing denture adhesives. Thu, 18 Feb 2010 17:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10017.htm GlaxoSmithKline and XenoPort receive FDA Complete Response letter for Horizant™ (GSK1838262/XP13512) for RLS http://www.gsk.com/media/pressreleases/2010/2010_us_pressrelease_10013.htm GlaxoSmithKline and XenoPort, Inc. Wednesday received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant™(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). Wed, 17 Feb 2010 02:15:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_us_pressrelease_10013.htm GSK launches new specialist unit to research and develop medicines for rare diseases http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10014.htm GSK today announces the formation of a new standalone unit specialising in the development and commercialisation of medicines for rare diseases. Thurs, 4 Feb 2010 14:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10014.htm GSK announces appointment of Philippe Fauchet as President of GSK Japan http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10015.htm GSK today announces the appointment of Philippe Fauchet as President of GSK Japan. Thurs, 4 Feb 2010 14:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10015.htm Results announcement for the fourth quarter 2009 http://www.gsk.com/investors/quarterly_results.htm GSK announces Q4 results 2009 Thu, 04 Feb 2010 12:00:00 GMT http://www.gsk.com/investors/quarterly_results.htm GSK’s Tykerb® receives accelerated approval for first-line combination treatment of hormone receptor positive, HER2+/ErbB2+ metastatic breast cancer http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10012.htm - Company progresses commitments to increase transparency Sat, 30 Jan 2010 02:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10012.htm Rotarix™ significantly reduced severe rotavirus gastroenteritis in African babies during their first year of life http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10011.htm The New England Journal of Medicine (NEJM) today published the first study demonstrating that Rotarix™, GlaxoSmithKline’s rotavirus vaccine, significantly prevented severe rotavirus gastroenteritis during the first year of life in African babies. Wed, 27 Jan 2010 22:00:00 GMT http://www.gsk.com/media/pressreleases/2010/2010_pressrelease_10011.htm